McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in an August 21, 2012 edition of Law360.com in an article entitled, “Generics Safe Harbor Question Could Derail Biosimilars.” Experts say biologic drug sponsors may have a powerful weapon to block competition from cheaper biosimilars if they can successfully argue that the generic drug law’s safe harbor from patent infringement expires the moment a drug wins regulatory approval. View the article